Babarović E, Valković T, Štifter S, Budisavljević I, Seili-Bekafigo I, Duletić-Načinović A, Lučin K, Jonjić N (2012) Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma. Am J Clin Pathol 137(6):870–878
Bain BJ, Clark DM, Wilkins BS (2019) Bone marrow pathology. Wiley, Oxford
Bao L, Wang Y, Lu M, Chu B, Shi L, Gao S, Fang L, Xiang Q (2020) Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients. Cancer Med 9(23):8962–8969
Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91(12):2214–2221
Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Sexton R (2015) Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 126(23):25
Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia 31(9):1915–1921
Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025–3031
Hallgrimsdottir T, Porwit A, Björkholm M, Rossmann E, Steingrimsdottir H, Lund SH, Kristinsson SY (2013) Bone marrow fibrosis in patients with multiple myeloma: a new prognostic factor for survival? Blood 122(21):1946
Kastritis E, Katodritou E, Pouli A, Hatzimichael E, Delimpasi S, Michalis E, Zomas A, Kartasis Z, Parcharidou A, Gika D (2011) Frequency and prognostic significance of hypercalcemia in patients with multiple myeloma: an analysis of the database of the Greek Myeloma Study Group. Blood 118(21):5083
Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT, Fairbanks RK, Weeks KA, Lee CM (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95(1):64–70
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33
Landgren O, Rajkumar SV (2016) New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res 22(22):5428–5433
Mittelman M (2003) The implications of anemia in multiple myeloma. Clin Lymphoma 4:S23–S29
Paul B, Zhao Y, Loitsch G, Feinberg D, Mathews P, Barak I, Dupuis M, Li Z, Rein L, Wang E (2020) The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. Cancer Med 9(16):5869–5880
Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B, Brenner H, Group GCSW (2015) Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 171(2):189–196
Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8(8):479–491
Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719–734
Rajkumar SV (2019) Multiple myeloma: Every year a new standard? Hematol Oncol 37:62–65
Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548–567
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, Kumar S, Hillengass J, Kastritis E, Richardson P (2014a) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014b) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548
Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91(1):101–119
Rajkumar SV, Kyle RA (2005) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80(10):1371–1382
Siegel RL, Miller KD, Jemal A (2015) (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29
Singhal N, Singh T, Singh ZN, Shome D, Gaiha M (2004) Histomorphology of multiple myeloma on bone marrow biopsy. Indian J Pathol Microbiol 47(3):359–363
Subramanian R, Basu D, Dutta TK (2007) Significance of bone marrow fibrosis in multiple myeloma. Pathology 39(5):512–515
Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. Br Med Bull 111(1):117–138
Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR, Peng Y (2016) A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Curr Med Res Opin 32(12):1989–1996
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E (2017) Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol 99(5):409–414
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Disclaimer:
This article is autogenerated using RSS feeds and has not been created or edited by OA JF.
Click here for Source link (https://www.springeropen.com/)
